Interventions of Interest:

  • AMX0035 (Amylyx Pharmaceuticals, Inc.)
  • oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.)

Amyotrophic lateral sclerosis (ALS) is a rare, progressive, neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. ALS often begins with localized weakness that will progress to involve most muscles. People with ALS typically die from respiratory muscle paralysis three to five years after symptom onset. The total annual cost to society for ALS is estimated to be $1 billion, with the highest costs including caregiving, ventilatory support, and hospital care.

For questions, please contact Maggie O’Grady, Program Manager, at mogrady@icer.org.

View the Key Stakeholder List.